Home > Publications database > Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade. > print

001     307633
005     20260115152727.0
024 7 _ |a 10.1136/jitc-2025-014090
|2 doi
024 7 _ |a pmid:41529910
|2 pmid
037 _ _ |a DKFZ-2026-00104
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Becker, Jürgen
|0 P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3
|b 0
|u dkfz
245 _ _ |a Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade.
260 _ _ |a London
|c 2026
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768487224_984431
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #DKTKZFB26#
520 _ _ |a Merkel cell carcinoma (MCC) exemplifies the paradigm of immunogenic tumors that nonetheless develop sophisticated immune evasion mechanisms. This is in line with the observation that MCC exhibits remarkable susceptibility to immune checkpoint inhibitors (ICIs), with responses in approximately half of patients with advanced disease in the first-line setting. However, 40-50% of patients show primary ICI resistance, while 20-30% of patients develop acquired ICI resistance on initial disease control. Still, the advent of ICI therapy represents a revolutionary rather than evolutionary advance in MCC management, fundamentally transforming outcomes from the dismal prognosis associated with conventional chemotherapy to durable responses extending substantially beyond 2 years. Still, important questions remain: (1) Is programmed cell death protein-1 or programmed death-ligand 1 inhibition more effective? (2) How long should ICI treatment continue? (3) What is the best choice of salvage therapy for patients with primary or acquired ICI resistance? (4) Which combination regimens can increase the share of patients benefiting from ICI? (5) Which patient/tumor characteristics predict response and its duration? Finally, (6) which timing of ICI therapy, that is, the neoadjuvant, adjuvant or therapeutic setting, offers the optimal overall outcomes for patients with MCC? A number of recent studies provide initial, but unfortunately not yet definitive answers.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Adjuvant
|2 Other
650 _ 7 |a Biomarker
|2 Other
650 _ 7 |a Immune Checkpoint Inhibitor
|2 Other
650 _ 7 |a Immunotherapy
|2 Other
650 _ 7 |a Neoadjuvant
|2 Other
650 _ 7 |a Immune Checkpoint Inhibitors
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Carcinoma, Merkel Cell: drug therapy
|2 MeSH
650 _ 2 |a Carcinoma, Merkel Cell: immunology
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Immunotherapy: methods
|2 MeSH
650 _ 2 |a Skin Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Skin Neoplasms: immunology
|2 MeSH
700 1 _ |a Lodde, Georg
|0 0000-0002-6930-2694
|b 1
700 1 _ |a Haist, Maximilian
|0 0000-0002-6720-7570
|b 2
700 1 _ |a Ugurel, Selma
|b 3
773 _ _ |a 10.1136/jitc-2025-014090
|g Vol. 14, no. 1, p. e014090 -
|0 PERI:(DE-600)2719863-7
|n 1
|p e014090
|t Journal for ImmunoTherapy of Cancer
|v 14
|y 2026
|x 2051-1426
909 C O |p VDB
|o oai:inrepo02.dkfz.de:307633
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)7bf2f090fe39a6cd6f0bccf5ea2d4fb3
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-24T13:16:43Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-24T13:16:43Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J IMMUNOTHER CANCER : 2022
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21